INEOS Quattro: conference call comments|NIH: improvement in certain indicators in H2, but still little visibility on M&A|Ardagh Group surprises with strong increase in glass EBITDA in Q4|Clariane : Satisfactory 2025 results thanks to strong recovery in H2 25 and B2/B+ ratings assigned by Moody’s and S&P|
INEOS Quattro: conference call comments|NIH : amélioration de certains indicateurs au S2 mais toujours peu de visibilité sur le M&A|Ardagh Group surprend avec une forte hausse de l’EBITDA verre au T4|Clariane : Résultats 2025 satisfaisants grâce à un bon rattrapage au 2nd semestre et ratings B2/B+ attribués par Moody’s et S&P|
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Following the departure of one analyst, we terminate the coverage with recommendation of the following issuers: Advanz Pharma, CBR Fashion Group, Ceconomy, Cheplapharm, Eurofins, Grenke, Grünenthal, IHO/Schaeffler, Ontex, Profine, Progroup, Stada, Teleperformance, Wepa and ZF Friedrichshafen. We intend to gradually resume coverage of some of these companies. Previous credit opinions and market recommendations are listed in the table on page 2.
Following the departure of one analyst, we terminate the coverage with recommendation of the following issuers: Advanz Pharma, CBR Fashion Group, Ceconomy, Cheplapharm, Eurofins, Grenke, Grünenthal, IHO/Schaeffler, Ontex, Profine, Progroup, Stada, Teleperformance, Wepa and ZF Friedrichshafen. We intend to gradually resume coverage of some of these companies. Previous credit opinions and market recommendations are listed in the table on page 2.
Coty: Q1 earnings down sharply as expected, slightly more optimistic guidance for Q2|NIH attempts risky return to primary market|Sappi: EBITDA plummets in Q4 and the situation is unlikely to improve in the short term|Worldline presents its transformation plan and plans a capital increase of € 500m|Air Baltic: a new liquidity injection seems unavoidable|
Coty : Résultats T1 en net repli comme attendu, guidance légèrement plus optimiste pour le T2|NIH tente un retour risqué sur le marché primaire|Sappi : l’EBITDA s’effondre au T4 et la situation ne devrait pas s’arranger à court-terme|Worldline présente son plan de transformation et compte réaliser une augmentation de capital de 500 m EUR|Air Baltic: a new liquidity injection seems unavoidable|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.